Evidence map›Paper›PMID 26791391›Full record

ArticleJournal of proteome research2016

Universal Solid-Phase Reversible Sample-Prep for Concurrent Proteome and N-Glycome Characterization.

Hui Zhou, Samantha Morley, Stephen Kostel, Michael R Freeman, Vivek Joshi, David Brewster, Richard S Lee

Open access · greenAbstract read
In one paragraph

Article in Journal of proteome research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hui ZhouDepartment of Urology, Boston Children's Hospital and Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Samantha MorleyDepartment of Urology, Boston Children's Hospital and Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Stephen KostelDepartment of Urology, Boston Children's Hospital and Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Michael R FreemanDivision of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center , Los Angeles, California 90048, United States.
Vivek JoshiEMD Millipore Corporation , Billerica, Massachusetts 01821, United States.
David BrewsterEMD Millipore Corporation , Billerica, Massachusetts 01821, United States.
Richard S LeeDepartment of Urology, Boston Children's Hospital and Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Boston Children's Hospital · USCedars-Sinai Medical Center · USHarvard University · US

Funding

Early Validation of Urinary Biomarkers of Renal ObstructionR01DK096238 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LEE, RICHARD SANG-YONG · 2013 to 2017
$1.3M
NIDDK NIH HHS R01 DK096238
6 · The paper itself

Abstract

We describe a novel solid-phase reversible sample-prep (SRS) platform that enables rapid sample preparation for concurrent proteome and N-glycome characterization for nearly all protein samples. SRS utilizes a uniquely functionalized, silica-based bead that has strong affinity toward proteins with minimal to no affinity for peptides and other small molecules. By leveraging this inherent size difference between proteins and peptides, SRS permits high-capacity binding of proteins, rapid removal of small molecules (detergents, metabolites, salts, peptides, etc.), extensive manipulation including enzymatic and chemical treatments on bead-bound proteins, and easy recovery of N-glycans and peptides. SRS was evaluated in a wide range of samples including glycoproteins, cell lysate, murine tissues, and human urine. SRS was also coupled to a quantitative strategy to investigate the differences between DU145 prostate cancer cells and its DIAPH3-silenced counterpart. Previous studies suggested that DIAPH3 silencing in DU145 induced transition to an amoeboid phenotype that correlated with tumor progression and metastasis. In this pilot study we identified distinct proteomic and N-glycomic alterations between them. A metastasis-associated tyrosine kinase receptor ephrin-type-A receptor (EPHA2) was highly up-regulated in DIAPH3-silenced cells, indicating a possible connection between EPHA2 and DIAPH3. Moreover, distinct alterations in the N-glycome were identified, suggesting cross-links between DIAPH3 and glycosyltransferase networks.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell Line, TumorChromatography, LiquidForminsGlycoproteinsHumansMice, Inbred C57BLProtein BindingProteomeReceptor, EphA2Silicon DioxideTandem Mass SpectrometryAdaptor Proteins, Signal TransducingDIAPH3 protein, humanForminsGlycoproteinsProteomeReceptor, EphA2Silicon Dioxideglycoproteinmembrane proteinN-glycomeplasmaproteomereversible solid phasesample-prepurine

Identifiers

PMID26791391
PMCPMC5440117
OpenAlexW2316441775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.